TG Therapeutics Inc


Prices are adjusted according to historical splits.

TG Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$2.20 billion
Book Value:
Revenue TTM:
$2.79 million
Operating Margin TTM:
Gross Profit TTM:
$2.52 million
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

TG Therapeutics Inc had its IPO on 1995-12-14 under the ticker symbol TGTX.

The company operates in the Healthcare sector and Biotechnology industry. TG Therapeutics Inc has a staff strength of 226 employees.

Stock update

Shares of TG Therapeutics Inc opened at $15 at the start of the last trading session i.e. 2023-03-30.

The stocks traded within a range of $14.27 - $15.06, and closed at $14.63.

This is a -1.48% slip from the previous day's closing price.

A total volume of 2,448,346 shares were traded at the close of the day’s session.

In the last one week, shares of TG Therapeutics Inc have increased by +2.67%.

TG Therapeutics Inc's Key Ratios

TG Therapeutics Inc has a market cap of $2.20 billion, indicating a price to book ratio of 10.8774 and a price to sales ratio of 249.2734.

In the last 12-months TG Therapeutics Inc’s revenue was $2.79 million with a gross profit of $2.52 million and an EBITDA of $-192536000. The EBITDA ratio measures TG Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, TG Therapeutics Inc’s operating margin was -6924.2% while its return on assets stood at -42.05% with a return of equity of -134.13%.

In Q4, TG Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 96.6%.

TG Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-1.43 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into TG Therapeutics Inc’s profitability.

TG Therapeutics Inc stock is trading at a EV to sales ratio of 198.8193 and a EV to EBITDA ratio of -4.3494. Its price to sales ratio in the trailing 12-months stood at 249.2734.

TG Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$193.57 million
Total Liabilities
$53.20 million
Operating Cash Flow
$16.27 million
Capital Expenditure
Dividend Payout Ratio

TG Therapeutics Inc ended 2023 with $193.57 million in total assets and $0 in total liabilities. Its intangible assets were valued at $193.57 million while shareholder equity stood at $58.59 million.

TG Therapeutics Inc ended 2023 with $305000.00 in deferred long-term liabilities, $53.20 million in other current liabilities, 146000.00 in common stock, $-1527033000.00 in retained earnings and $799000.00 in goodwill. Its cash balance stood at $102.30 million and cash and short-term investments were $161.68 million. The company’s total short-term debt was $1,581,000 while long-term debt stood at $71.14 million.

TG Therapeutics Inc’s total current assets stands at $168.27 million while long-term investments were $12.40 million and short-term investments were $59.37 million. Its net receivables were $0 compared to accounts payable of $42.02 million and inventory worth $0.

In 2023, TG Therapeutics Inc's operating cash flow was $16.27 million while its capital expenditure stood at $3000.

Comparatively, TG Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

TG Therapeutics Inc stock is currently trading at $14.63 per share. It touched a 52-week high of $19.59 and a 52-week low of $19.59. Analysts tracking the stock have a 12-month average target price of $19.88.

Its 50-day moving average was $15.9 and 200-day moving average was $9.27 The short ratio stood at 6.88 indicating a short percent outstanding of 0%.

Around 885.7% of the company’s stock are held by insiders while 6459.6% are held by institutions.

Frequently Asked Questions About TG Therapeutics Inc

The stock symbol (also called stock or share ticker) of TG Therapeutics Inc is TGTX

The IPO of TG Therapeutics Inc took place on 1995-12-14

Similar Industry Stocks (Biotechnology)

Last Price
Unit Corp (UNTC)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price


TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell diseases. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company’s development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma; TG-1701 is an orally available and covalently-bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; Novimmune SA; and Jubilant Biosys, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.


2 Gansevoort Street, New York, NY, United States, 10014